24 results on '"Borba, Eduardo F."'
Search Results
2. Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients
- Author
-
Silva, Clovis A., Medeiros-Ribeiro, Ana C., Kupa, Leonard V. K., Yuki, Emily F. N., Pasoto, Sandra G., Saad, Carla G. S., Fusco, Solange R. G., Pereira, Rosa M. R., Shinjo, Samuel K., Halpern, Ari S. R., Borba, Eduardo F., Souza, Fernando H. C., Guedes, Lissiane K. N., Miossi, Renata, Bonfiglioli, Karina R., Domiciano, Diogo S., Shimabuco, Andrea Y., Andrade, Danieli C. O., Seguro, Luciana P. C., Fuller, Ricardo, Sampaio-Barros, Percival D., Assad, Ana P. L., Moraes, Julio C. B., Goldenstein-Schainberg, Claudia, Giardini, Henrique A. M., Silva, Henrique C., Martins, Victor A. O., Villamarin, Lorena E. B., Novellino, Renata S., Sales, Lucas P., Araújo, Carlo S. R., Silva, Matheus S. R., Filho, Dilson M. N., Lopes, Marta H., Duarte, Alberto J. S., Kallas, Esper G., Aikawa, Nadia E., and Bonfa, Eloisa
- Published
- 2022
- Full Text
- View/download PDF
3. Adrenal steroidogenesis and ovarian reserve in adult childhood-onset systemic lupus erytematosus patients
- Author
-
Lourenço, Daniela M. R., Araújo, Daniel B., Aikawa, Nadia E., Yamakami, Lucas Y. S., Borba, Eduardo F., Maciel, Gustavo A. R., Soares-Junior, Jose M., Baracat, Edmund C., Pereira, Rosa M. R., Bonfa, Eloisa, and Silva, Clovis A.
- Published
- 2021
- Full Text
- View/download PDF
4. SARS-CoV-2 infection, gut dysbiosis, and heterogeneous clinical results of hydroxychloroquine on COVID-19 therapy—Is there a link?
- Author
-
Balmant, Bianca D., Torrinhas, Raquel S., Rocha, Ilanna M., Fonseca, Danielle C., Formiga, Francisco F.C., Bonfá, Eloisa S.D.O., Borba, Eduardo F., and Waitzberg, Dan L.
- Published
- 2021
- Full Text
- View/download PDF
5. Hydroxychloroquine blood levels in stable lupus nephritis under low dose (2–3 mg/kg/day): 12-month prospective randomized controlled trial
- Author
-
Zanetti, Caio B., Pedrosa, Tatiana, Kupa, Léonard de V. K., Aikawa, Nadia E., Borba, Eduardo F., Vendramini, Margarete B. G., Silva, Clovis A., Pasoto, Sandra G., and Bonfa, Eloisa
- Published
- 2021
- Full Text
- View/download PDF
6. Transcriptomic signatures of classical monocytes reveal proinflammatory modules and heterogeneity in polyarticular juvenile idiopathic arthritis.
- Author
-
Hounkpe, Bidossessi W., Sales, Lucas P., Ribeiro, Surian C. R., Perez, Mariana O., Caparbo, Valéria F., Domiciano, Diogo Souza, Figueiredo, Camille P., Pereira, Rosa M. R., and Borba, Eduardo F.
- Subjects
JUVENILE idiopathic arthritis ,MONOCYTES ,TRANSCRIPTOMES ,GENE expression ,RHEUMATOID factor - Abstract
Introduction: Polyarticular juvenile idiopathic arthritis (pJIA) is a childhood-onset autoimmune disease. Immune cells contribute to persistent inflammation observed in pJIA. Despite the crucial role of monocytes in arthritis, the precise involvement of classical monocytes in the pathogenesis of pJIA remains uncertain. Here, we aimed to uncover the transcriptomic patterns of classical monocytes in pJIA, focusing on their involvement in disease mechanism and heterogeneity. Methods: A total of 17 healthy subjects and 18 premenopausal women with pJIA according to ILAR criteria were included. Classical monocytes were isolated, and RNA sequencing was performed. Differential expression analysis was used to compare pJIA patients and healthy control group. Differentially expressed genes (DEGs) were identified, and gene set enrichment analysis (GSEA) was performed. Using unsupervised learning approach, patients were clustered in two groups based on their similarities at transcriptomic level. Subsequently, these clusters underwent a comparative analysis to reveal differences at the transcriptomic level. Results: We identified 440 DEGs in pJIA patients of which 360 were upregulated and 80 downregulated. GSEA highlighted TNF-α and IFN-γ response. Importantly, this analysis not only detected genes targeted by pJIA therapy but also identified new modulators of immuno-inflammation. PLAUR, IL1B, IL6, CDKN1A, PIM1, and ICAM1 were pointed as drivers of chronic hyperinflammation. Unsupervised learning approach revealed two clusters within pJIA, each exhibiting varying inflammation levels. Conclusion: These findings indicate the pivotal role of immuno-inflammation driven by classical monocytes in pJIA and reveals the existence of two subclusters within pJIA, regardless the positivity of rheumatoid factor and anti-CCP, paving the way to precision medicine. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Time to diagnosis in systemic lupus erythematosus: Associated factors and its impact on damage accrual and mortality. Data from a multi-ethnic, multinational Latin American lupus cohort.
- Author
-
Nieto, Romina, Quintana, Rosana, Zavala-Flores, Ernesto, Serrano, Rosa, Roberts, Karen, Catoggio, Luis J, García, Mercedes A, Berbotto, Guillermo A, Saurit, Verónica, Bonfa, Eloisa, Borba, Eduardo F, Lavras Costallat, Lilian T, Da Silva, Nilzio A, Sato, Emilia I, Tavares Brenol, Joao C, Massardo, Loreto, Neira, Oscar J, Vázquez, Gloria, Guibert Toledano, Marlene, and Pascual-Ramos, Virginia
- Subjects
DELAYED diagnosis ,SYSTEMIC lupus erythematosus ,HEALTH insurance ,SYMPTOMS ,MORTALITY ,DIAGNOSIS - Abstract
Background: Systemic lupus erythematosus (SLE) often mimics symptoms of other diseases, and the interval between symptom onset and diagnosis may be long in some of these patients. Aims: To describe the characteristics associated with the time to SLE diagnosis and its impact on damage accrual and mortality in patients with SLE from a Latin American inception cohort. Methods: Patients were from a multi-ethnic, multi-national Latin-American SLE inception cohort. All participating centers had specialized lupus clinics. Socio-demographic, clinical/laboratory, disease activity, damage, and mortality between those with a longer and a shorter time to diagnosis were compared using descriptive statistical tests. Multivariable Cox regression models with damage accrual and mortality as the end points were performed, adjusting for age at SLE diagnosis, gender, ethnicity, level of education, and highest dose of prednisone for damage accrual, plus highest dose of prednisone, baseline SLEDAI, and baseline SDI for mortality. Results: Of the 1437 included in these analyses, the median time to diagnosis was 6.0 months (Q1–Q3 2.4–16.2); in 721 (50.2%) the time to diagnosis was longer than 6 months. Patients whose diagnosis took longer than 6 months were more frequently female, older at diagnosis, of Mestizo ethnicity, not having medical insurance, and having "non-classic" SLE symptoms. Longer time to diagnosis had no impact on either damage accrual (HR 1.09, 95% CI 0.93–1.28, p = 0.300) or mortality (HR 1.37, 95% CI 0.88–2.12, p = 0.200). Conclusions: In this inception cohort, a maximum time of 24 months with a median of 6 months to SLE diagnosis had no apparent negative impact on disease outcomes (damage accrual and mortality). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Plasma kinetics of an LDL-like non-protein nanoemulsion and transfer of lipids to high-density lipoprotein (HDL) in patients with rheumatoid arthritis
- Author
-
Pozzi, Fernanda S., Maranhão, Raul C., Guedes, Lissiane K., Borba, Eduardo F., Laurindo, Ieda M.M., Bonfa, Eloisa, and Vinagre, Carmen G.
- Published
- 2015
- Full Text
- View/download PDF
9. Juvenile idiopathic arthritis activity and function ability: deleterious effects in periodontal disease?
- Author
-
Pugliese, Camila, van der Vinne, Roberta T. A., Campos, Lucia M. A., Guardieiro, Priscila R., Saviolli, Cynthia, Bonfá, Eloisa, Pereira, Rosa M. R., Viana, Vilma S., Borba, Eduardo F., and Silva, Clovis A.
- Published
- 2016
- Full Text
- View/download PDF
10. Predictors of severe hemolytic anemia and its impact on major outcomes in systemic lupus erythematosus: Data from a multiethnic Latin American cohort.
- Author
-
González, Luis Alonso, Alarcón, Graciela S., Harvey, Guillermina B., Quintana, Rosana, Pons-Estel, Guillermo J., Ugarte-Gil, Manuel F., Vásquez, Gloria, Catoggio, Luis J., García, Mercedes A., Borba, Eduardo F., Da Silva, Nilzio A., Tavares Brenol, João C., Guibert Toledano, Marlene, Massardo, Loreto, Neira, Oscar, Pascual-Ramos, Virginia, Amigo, Mary-Carmen, Barile-Fabris, Leonor A., García De La Torre, Ignacio, and Alfaro-Lozano, José
- Subjects
HEMOLYTIC anemia ,AUTOIMMUNE hemolytic anemia ,SYSTEMIC lupus erythematosus - Abstract
Objective: To determine the predictors of the occurrence of severe autoimmune hemolytic anemia (AIHA) and its impact on damage accrual and mortality in SLE patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Circulating Follicular Helper–Like T Cells in Systemic Lupus Erythematosus: Association With Disease Activity
- Author
-
Choi, Jin-Young, Hsi-en Ho, John, Pasoto, Sandra G., Bunin, Viviane, Kim, Sang Taek, Carrasco, Solange, Borba, Eduardo F., Gonçalves, Celio R., Costa, Priscila R., Kallas, Esper G., Bonfa, Eloisa, and Craft, Joseph
- Published
- 2015
- Full Text
- View/download PDF
12. Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome.
- Author
-
Signorelli, Flavio, Balbi, Gustavo Guimarães Moreira, Aikawa, Nadia E, Silva, Clovis A, Kupa, Léonard de Vinci Kanda, Medeiros-Ribeiro, Ana C, Yuki, Emily FN, Pasoto, Sandra G, Saad, Carla GS, Borba, Eduardo F, Seguro, Luciana Parente Costa, Pedrosa, Tatiana, Oliveira, Vitor Antonio de Angeli, Costa, Ana Luisa Cerqueira de Sant'Ana, Ribeiro, Carolina T, Santos, Roseli Eliana Beseggio, Andrade, Danieli Castro Oliveira, and Bonfá, Eloisa
- Subjects
COVID-19 vaccines ,PHOSPHOLIPID antibodies ,COVID-19 ,IMMUNE response ,ANTIPHOSPHOLIPID syndrome - Abstract
Objective: Coronavirus disease 19 (COVID-19) has an increased risk of coagulopathy with high frequency of antiphospholipid antibodies (aPL). Recent reports of thrombosis associated with adenovirus-based vaccines raised concern that SARS-CoV-2 immunization in primary antiphospholipid syndrome (PAPS) patients may trigger clotting complications. Our objectives were to assess immunogenicity, safety, and aPL production in PAPS patients, after vaccinating with Sinovac-CoronaVac, an inactivated virus vaccine against COVID-19. Methods: This prospective controlled phase-4 study of PAPS patients and a control group (CG) consisted of a two-dose Sinovac-CoronaVac (D0/D28) and blood collection before vaccination (D0), at D28 and 6 weeks after second dose (D69) for immunogenicity/aPL levels. Outcomes were seroconversion (SC) rates of anti-SARS-CoV-2 S1/S2 IgG and/or neutralizing antibodies (NAb) at D28/D69 in naïve participants. Safety and aPL production were also assessed. Results: We included 44 PAPS patients (31 naïve) and 132 CG (108 naïve) with comparable age (p =0.982) and sex (p >0.999). At D69, both groups had high and comparable SC (83.9% vs. 93.5%, p =0.092), as well as NAb positivity (77.4% vs. 78.7%, p =0.440), and NAb-activity (64.3% vs. 60.9%, p =0.689). Thrombotic events up to 6 months or other moderate/severe side effects were not observed. PAPS patients remained with stable aPL levels throughout the study at D0 vs. D28 vs. D69: anticardiolipin (aCL) IgG (p =0.058) and IgM (p =0.091); anti-beta-2 glycoprotein I (aβ2GPI) IgG (p =0.513) and IgM (p =0.468). Conclusion: We provided novel evidence that Sinovac-CoronaVac has high immunogenicity and safety profile in PAPS. Furthermore, Sinovac-CoronaVac did not trigger thrombosis nor induced changes in aPL production. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Hydroxychloroquine increased cholesterol transfer to high-density lipoprotein in systemic lupus erythematosus: A possible mechanism for the reversal of atherosclerosis in the disease.
- Author
-
Lang, Maria G, Vinagre, Carmen GC, Bonfa, Eloisa, Freitas, Fatima R, Pasoto, Sandra G, Brito, Tatiane S, Seguro, Luciana PC, Maranhão, Raul C, and Borba, Eduardo F
- Subjects
HDL cholesterol ,SYSTEMIC lupus erythematosus ,BLOOD lipids ,HYDROXYCHLOROQUINE ,BODY mass index ,ATHEROSCLEROSIS - Abstract
Introduction: The beneficial effect of hydroxychloroquine (HCQ) in decreasing LDL levels on Systemic Lupus Erythematosus (SLE) is well defined. The influence of this drug on HDL levels is still under debate and information about its effect on cholesterol reverse transport is lacking. Objective: To evaluate the effects of HCQ on HDL levels and the transfer of lipids to this lipoprotein in SLE. Methods: Nineteen SLE patients using only HCQ (SLE WITH HCQ), 19 SLE patients without any therapy (SLE WITHOUT THERAPY), and 19 healthy controls (CONTROL) were included. All three groups were premenopausal women age- and gender-matched. Serum lipids and apolipoproteins were determined by commercial kits. An in vitro transfer of four lipids (
14 C-Phospolipid,3 H-Cholesteryl ester,3 H-Triglyceride, and14 C-Unesterified cholesterol) from a radioactively labeled nanoemulsion donor to HDL was performed in all participants. Results: Groups had comparable mean age, weight, height, BMI(body mass index), and waist circumference (p >.05). Mean HDL levels were higher in SLE WITH HCQ group compared to SLE WITHOUT THERAPY(58.37 ± 14.04 vs 49.79 ± 8.0 mg/dL; p <.05) but lower than CONTROL (58.37 ± 14.04 vs 68.58 ± 9.99 mg/dL; p <.05). Total cholesterol (TC) and LDL levels were also significantly lower in SLE WITH HCQ compared SLE WITHOUT THERAPY(148.16 ± 16.43 vs 167.11 ± 30.18 mg/dL; p <.05, 75.05 ± 22.52 vs 96.05 ± 25.63 mg/dL; p <.05) and CONTROL (148.16 ± 16.43 vs 174.11 ± 23.70 mg/dL; p <.05, 75.05 ± 22.52 vs 88.53 ± 20.24 mg/dL; p <.05). The in vitro lipid transfer to HDL study revealed a significant difference among the three groups (p =.002) with a higher transfer of unesterified cholesterol(UC) in SLE WITH HCQ compared to SLE WITHOUT THERAPY(5.40 ± 1.05% vs. 4.44 ± 1.05%; p <.05). The latter was significantly decreased compared to CONTROL (5.40 ± 1.05% vs. 5.99 ± 1.71%; p <.05).The percentages of transfer of triacylglycerol (4.93 ± 0.69% vs. 4.50 ± 0.69% vs. 5.14 ± 1.01%; p =.054), esterified cholesterol (5.24 ± 0.70% vs. 4.96 ± 0.89% vs. 5.69 ± 1.27%; p =.079), and phospholipid (15.67 ± 1.03% vs. 15.34 ± 1.44% vs. 16.47 ± 1.89%; p =.066) were similar among groups. Conclusion: The present study is the first to demonstrate that HCQ promoted a higher transfer of unesterified cholesterol which may account for the increased HDL levels in lupus patients under HCQ. This desirable effect may underlie the reported reduced atherosclerosis in SLE. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
14. 2019-EULAR/ACR classification criteria domains at diagnosis: predictive factors of long-term damage in systemic lupus erythematosus.
- Author
-
Insfrán, Carlos E., Aikawa, Nadia E., Pasoto, Sandra G., Filho, Dilson M. N., Formiga, Francisco F. C., Pitta, Ana C., Borba, Eduardo F., Ribeiro, Carolina T., Silva, Clovis A., and Bonfa, Eloisa
- Subjects
SYSTEMIC lupus erythematosus ,PHOSPHOLIPID antibodies ,LOGISTIC regression analysis ,DISEASE duration - Abstract
The objective of this study is to assess the role of the 2019-European League Against Rheumatism/American College of Rheumatology (2019-EULAR/ACR) classification criteria at diagnosis and its domains in predicting long-term damage in systemic lupus erythematosus(SLE). We performed a retrospective analysis using an electronic chart database utilized in routine clinical care of SLE patients and established in 2000 in a tertiary hospital. Two hundred and nine consecutive SLE patients with disease onset ≥18 years old and long disease duration were included. Cumulative damage at the last visit was scored using the SLICC/ACR-Damage Index (SDI). The median age at SLE diagnosis was 28 years (18–63), disease duration was 14 years (8–25), and 88% were females. Damage (SDI≥1) was observed in 116/209 (55%). Patients with (SDI≥1, n=116) and without damage (SDI=0, n=93) had similar median disease duration [14 (8–25) vs. 12 (8–25) years, p=0.090] and age at diagnosis [23 (18–55) vs. 23 (18–56) years, p=0.998]. No correlation was observed between total 2019-EULAR/ACR score at diagnosis and SDI at last visit (r=0.007, p=0.913). Presence of renal domain at diagnosis was associated with renal damage at last visit (OR=3.6, 95%CI 1.2–10.4, p=0.017) and antiphospholipid antibodies domain predicted neuropsychiatric damage (OR=3.0, 95%CI 1.2–7.6, p=0.015). A ROC analysis identified that a cut-off >24 in 2019-EULAR/ACR score could predict a trend for renal damage (p=0.077) with a lower renal survival (Kaplan-Meier curve) for patients above this limit (p=0.029). A multivariate logistic regression analysis revealed that 2019-EULAR/ACR score >24 at diagnosis (OR 4.583, 95%CI 1.052–19.962, p=0.043) was independently associated with renal damage. Specific domains in the 2019-EULAR/ACR criteria at diagnosis were associated with long-term organ-specific damage, particularly renal and neuropsychiatric harm. A 2019-EULAR/ACR score >24 predicted worse renal survival. Key Points • Presence of renal domain of the 2019-EULAR/ACR classification criteria at diagnosis was associated with long-term renal damage. • Presence of antiphospholipid antibodies domain at diagnosis was associated with long-term neuropsychiatric damage. • A 2019-EULAR/ACR overall score >24 at diagnosis was independently associated with renal damage and predicted worse renal long-term survival. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Impact of Distinct Therapies on Antibody Response to SARS‐CoV‐2 Vaccine in Systemic Lupus Erythematosus.
- Author
-
Yuki, Emily F. N., Borba, Eduardo F., Pasoto, Sandra G., Seguro, Luciana P., Lopes, Michelle, Saad, Carla G. S., Medeiros‐Ribeiro, Ana Cristina, Silva, Clovis A., de Andrade, Danieli C. O., Kupa, Leonard de Vinci K., Betancourt, Lorena, Bertoglio, Isabela, Valim, Juliana, Hoff, Camilla, Formiga, Francisco F. C., Pedrosa, Tatiana, Kallas, Esper G., Aikawa, Nadia E., and Bonfa, Eloisa
- Subjects
IMMUNOGLOBULINS ,COVID-19 vaccines ,SYSTEMIC lupus erythematosus ,UNIVARIATE analysis ,MYCOPHENOLIC acid - Abstract
Objective: To date, the only study that has assessed the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2 mRNA) vaccine in systemic lupus erythematosus (SLE) observed a moderate response, but the sample size precluded an accurate analysis of the effect of individual drugs. Therefore, we evaluated the immunogenicity of an inactivated SARS‐CoV‐2 vaccine (Sinovac‐CoronaVac) and the influence of different medications in SLE. Safety was also assessed. Methods: We conducted a prospective controlled study of 232 SARS‐CoV‐2–naive SLE patients and 58 SARS‐CoV‐2–naive controls who were vaccinated with 2 doses of Sinovac‐CoronaVac with a 28‐day interval (day 0/day 28 [D0/D28]). Immunogenicity analysis at D0/D28 and D69 included anti‐SARS‐CoV‐2 S1/S2 IgG seroconversion (SC) and neutralizing antibodies (NAb) positivity. The influence of individual drugs on immune response and safety was assessed. Results: Patients and controls were well balanced for age (P = 0.771). At D69, SLE patients showed a moderate SC (70.2% versus 98.1%; P < 0.001) and moderate frequency of NAb positivity (61.5% versus 84.6%; P = 0.002), although both frequencies were lower than in controls. Factors associated with lower SC in univariate analysis at D69 were prednisone use (odds ratio [OR] 0.215 [95% confidence interval (95% CI) 0.108–0.427], P < 0.001) and mycophenolate mofetil (MMF) use (OR 0.201 [95% CI 0.107–0.378], P < 0.001), whereas hydroxychloroquine (HCQ) use led to a 2.5 increase in SC (P = 0.011). SLE patients who were receiving HCQ monotherapy had similar SC to controls at D69 (100% versus 98.1%; P = 1.000). In multivariate analysis, prednisone and MMF use were independently associated with lower SC (P < 0.001) and NAb positivity (P < 0.001). Safety analysis revealed no moderate/severe adverse events. Conclusion: Sinovac‐CoronaVac has a moderate immunogenicity in SARS‐CoV‐2–naive SLE patients with an excellent safety profile. We further demonstrate that HCQ may improve SC, whereas prednisone and MMF had a major deleterious effect in vaccine response, reinforcing the need to investigate the role of temporary MMF withdrawal or a vaccine‐booster dose (ClinicalTrials.gov identifier: NCT04754698). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Avoiding misclassification of thrombotic primary antiphospholipid syndrome as systemic lupus erythematosus (SLE): What are the best-performing SLE classification criteria?
- Author
-
Signorelli, Flavio, Balbi, Gustavo Guimarães Moreira, Bonfá, Eloisa, Borba, Eduardo F, and Andrade, Danieli Castro de Oliveira
- Subjects
SYSTEMIC lupus erythematosus ,ANTIPHOSPHOLIPID syndrome - Abstract
Background: Systemic lupus erythematosus (SLE) and Primary Antiphospholipid Syndrome (PAPS) overlap clinical and immunological features. Therefore, misclassification of PAPS patients as SLE is a concern. The ACR/EULAR 2019 SLE classification has never been studied in PAPS. Objective: To verify if the ACR/EULAR 2019 SLE classification can correctly classify a PAPS patient as not having SLE and compare its performance with the SLICC 2012 SLE classification. Methods: One-hundred thrombotic PAPS patients who fulfilled the Sidney criteria were consecutively screened and those who attended the inclusion criteria were submitted to ACR/EULAR 2019 and SLICC 2012 classifications. Results: Sixty-seven PAPS patients were included in this study. The majority was female (89.6%) with median age at study inclusion of 45 years (35–53) and median PAPS disease duration of 13 years (8–19). PAPS correct classification was observed more often with ACR/EULAR 2019 than SLICC 2021 criteria (94.0% vs. 64.2%; p < 0.001). The 4 misclassified patients in ACR/EULAR 2019 were also misclassified in SLICC 2012. The comparison of misclassified patients to those correctly not classified as SLE resulted, for both criteria, in higher frequencies of hematological domain [ACR/EULAR 2019 (100% vs. 28.6%, p = 0.010) and SLICC 2012 (95.8% vs. 11.6%, p < 0.001)]. Further analysis of hematological manifestations revealed that for the ACR/EULAR 2019 leukopenia (100% vs. 22.2%, p = 0.004) and for the SLICC 2012 leukopenia/lymphopenia (91.7% vs. 7%, p < 0.001) were more frequent in misclassified group. Proteinuria (20.8% vs. 0%, p = 0.004) and low complement (45.8% vs. 20.9%, p = 0.033) were also more often observed in the incorrectly SLICC 2012 classified patients. Conclusion: ACR/EULAR 2019 had high accuracy for distinguishing PAPS from SLE, whereas the SLICC 2012 incorrectly classified more than one third of the PAPS patients as having SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. Short- and Long-Term Outcome of Systemic Lupus Erythematosus Peripheral Neuropathy: Bimodal Pattern of Onset and Treatment Response.
- Author
-
Fargetti, Simone, Ugolini-Lopes, Michelle R., Pasoto, Sandra G., Seguro, Luciana P. C., Shinjo, Samuel K., Bonfa, Eloisa, and Borba, Eduardo F.
- Published
- 2021
- Full Text
- View/download PDF
18. Factors associated with neuropsychiatric involvement in Latin American patients with systemic lupus erythematosus.
- Author
-
Barile-Fabris, Leonor A, Fragoso-Loyo, Hilda, Wojdyla, Daniel, Quintana, Rosana, Pons-Estel, Guillermo J, Catoggio, Luis J, García, Mercedes A, Saurit, Verónica, Drenkard, Cristina, Bonfa, Eloisa, Borba, Eduardo F, Sato, Emilia, Tavares Brenol, Joao C, Cavalcanti, Fernando, Da Silva, Nilzio A, Lavras Costallat, Lilian T, Guibert Toledano, Marlene, Massardo, Loreto, Neira, Oscar, and Cardiel, Mario H
- Subjects
LATIN Americans ,SYSTEMIC lupus erythematosus ,HEMOLYTIC anemia ,PROGNOSIS ,DISEASE duration ,DISEASE progression - Abstract
Introduction: Factors related to presentation of neuropsychiatric (NP) SLE manifestations, early in the course of the disease, and during follow up have not been clearly established. Purpose: To identify disease and non-disease related factors associated with NP manifestations in early SLE. Methods: We included 1193 patients from the GLADEL inception cohort free of NP involvement at cohort entry. We evaluated the association of demographic, clinical and laboratory data with NP involvement during follow-up. Statistical methods: Independent factors associated with NP involvement were identified using a multivariable Cox regression model. Results: Factors independently associated with NP manifestations were: mestizo ethnicity (HR 1.701, 95% CI 1.282–2.258, p = 0.0002), myalgias/myositis (HR 1.832, 95% CI 1.335–2.515, p = 0.0002), pneumonitis (HR 2.476, 95% CI 1.085–5.648, p = 0.0312), shrinking lung (HR 2.428, 95% CI 1.074–5.493, p = 0.0331) and hemolytic anemia (HR 1.629, 95% CI 1.130–2.347, p = 0.0089). Longer disease duration at cohort entry (13 to 24 months) was associated with a lower risk of developing NP manifestations (HR 0.642, 95% CI 0.441–0.934, p = 0.0206). Conclusions: Patients with myalgias/myositis, pneumonitis, shrinking lung and hemolytic anemia are at higher risk of NP involvement, whereas longer disease duration at cohort entry is associated with a lower risk of developing NP involvement. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis.
- Author
-
Pedrosa, Tatiana N, Pasoto, Sandra G, Aikawa, Nadia E, Yuki, Emily FN, Borba, Eduardo F, Filho, Julio CR Ferreira, Carricondo, Pedro C, Zanetti, Caio B, Conde, Paola G, Duarte, Nilo JC, Fontoura, Nicole, Romano, Paschoalina, Carvalho, Valdemir M, Silva, Clovis A, and Bonfa, Eloisa
- Subjects
LUPUS nephritis ,LIQUID chromatography-mass spectrometry ,HYDROXYCHLOROQUINE ,SYSTEMIC lupus erythematosus - Abstract
Objectives: It is unknown if hydroxychloroquine blood level dynamics impact flare rates in lupus nephritis patients. We prospectively evaluated hydroxychloroquine levels to determine which blood-based patterns are more associated with disease activity. Methods: In total, 82 lupus nephritis patients under a prescribed hydroxychloroquine dose of 4–5.5 mg/kg actual body weight (maximum 400 mg/day) for ≥3 months were evaluated at baseline and 7 months. Hydroxychloroquine blood levels were determined by liquid chromatography-tandem mass spectrometry. Flare was defined as increase ≥3 in the Systemic Lupus Erythematosus Disease Activity Index 2000 score and/or a change or increase in therapy. Results: Overall, 9/82(11%) patients had flares during follow-up and had lower baseline hydroxychloroquine blood levels than those without flares (220.4 (53.5–1471.1) vs. 1006.3 (53.5–2137.8) ng/ml, p = 0.013). The hydroxychloroquine blood level cut-off that best predicted flares was 613.5 ng/ml (odds ratio = 8.67, 95% confidence interval: 1.66–45.18, p = 0.006). For 77 (94%) patients, the 7-month hydroxychloroquine level dynamics was evaluated and revealed: 59/77 (77%) had a persistent pattern of adequate (41/77(53%)) or fluctuating (18/77 (23%)) levels, with a low and comparable risk of flares (2/41 (5%) vs. 1/18 (5%), p = 1.000). The remaining group had persistent low levels (18/77 (23%)) and their flare frequency was significantly higher than the adequate group (5/18 (28%) vs. 2/41 (5%), p = 0.023). The frequencies of adequate/inadequate hydroxychloroquine blood levels in patients were comparable at baseline and 7 months (McNemar's test, p = 0.480). Conclusion: We provide novel evidence that hydroxychloroquine blood-level patterns (persistently low, adequate, or intermittent) have distinct impacts on flare rates in lupus nephritis patients. These findings reinforce the need of routine hydroxychloroquine measurements to maintain the appropriate blood levels. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
20. Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes.
- Author
-
Mackay, Meggan, Dall'Era, Maria, Fishbein, Joanna, Kalunian, Kenneth, Lesser, Martin, Sanchez‐Guerrero, Jorge, Levy, Deborah M., Silverman, Earl, Petri, Michelle, Arriens, Cristina, Lewis, Edmund J., Korbet, Stephen M., Conti, Fabrizio, Tesar, Vladimir, Hruskova, Zdenka, Borba, Eduardo F., Bonfa, Eloisa, Chan, Tak Mao, Rathi, Manish, and Gupta, K. L.
- Subjects
LUPUS nephritis ,ACUTE kidney failure ,BIOMARKERS ,CHRONIC kidney failure ,CLINICAL trials ,CREATININE ,DATABASES ,MEDICAL information storage & retrieval systems ,KIDNEY diseases ,LONGITUDINAL method ,PROTEINURIA ,RACE ,RISK assessment ,THERAPEUTICS ,PROPORTIONAL hazards models ,SEVERITY of illness index ,DISEASE progression ,DIAGNOSIS - Abstract
Objective: End points currently used in lupus nephritis (LN) clinical trials lack uniformity and questionably reflect long‐term kidney survival. This study was undertaken to identify short‐term end points that predict long‐term kidney outcomes for use in clinical trials. Methods: A database of 944 patients with LN was assembled from 3 clinical trials and 12 longitudinal cohorts. Variables from the first 12 months of treatment after diagnosis of active LN (prediction period) were assessed as potential predictors of long‐term outcomes in a 36‐month follow‐up period. The long‐term outcomes examined were new or progressive chronic kidney disease (CKD), severe kidney injury (SKI), and the need for permanent renal replacement therapy (RRT). To predict the risk for each outcome, hazard index tools (HITs) were derived using multivariable analysis with Cox proportional hazards regression. Results: Among 550 eligible subjects, 54 CKD, 55 SKI, and 22 RRT events occurred. Variables in the final CKD HIT were prediction‐period CKD status, 12‐month proteinuria, and 12‐month serum creatinine level. The SKI HIT variables included prediction‐period CKD status, International Society of Nephrology (ISN)/Renal Pathology Society (RPS) class, 12‐month proteinuria, 12‐month serum creatinine level, race, and an interaction between ISN/RPS class and 12‐month proteinuria. The RRT HIT included age at diagnosis, 12‐month proteinuria, and 12‐month serum creatinine level. Each HIT validated well internally (c‐indices 0.84–0.92) and in an independent LN cohort (c‐indices 0.89–0.92). Conclusion: HITs, derived from short‐term kidney responses to treatment, correlate with long‐term kidney outcomes, and now must be validated as surrogate end points for LN clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
21. Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL).
- Author
-
Ugarte-Gil, Manuel Francisco, Wojdyla, Daniel, Pons-Estel, Guillermo J., Catoggio, Luis J., Drenkard, Cristina, Sarano, Judith, Berbotto, Guillermo A., Borba, Eduardo F., Sato, Emilia Inoue, Brenol, João C. Tavares, Uribe, Oscar, Gómez, Luis A. Ramirez, Guibert-Toledano, Marlene, Massardo, Loreto, Cardiel, Mario H., Silveira, Luis H., Chacón-Diaz, Rosa, Alarcón, Graciela S., Pons-Estel, Bernardo A., and Tavares Brenol, João C
- Abstract
Objective: To evaluate disease activity statuses' (DAS') impact on systemic lupus erythematosus (SLE) outcomes.Materials and Methods: Four DAS were defined: remission off-therapy: SLE Disease Activity Index (SLEDAI)=0, no prednisone or immunosuppressive drugs (IS); remission on-therapy: SLEDAI=0, prednisone ≤5 mg/day and/or IS (maintenance); low (L) DAS: SLEDAI ≤4, prednisone ≤7.5 mg/day and/or IS (maintenance); non-optimally controlled: SLEDAI >4 and/or prednisone >7.5 mg/day and/or IS (induction). Antimalarials were allowed in all. Predefined outcomes were mortality, new damage (increase of at least one Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index (SDI) point) and severe new damage (increase of at least 3 SDI points). Univariable and multivariable Cox regression models were performed to define the impact of DAS, as time-dependent variable, on these outcomes.Results: 1350 patients were included, 79 died during follow-up, 606 presented new and 177 severe new damage. In multivariable analyses, remission (on/off-therapy) was associated with a lower risk of new (HR 0.60; 95% CI 0.43 to 0.85), and of severe new damage (HR 0.32; 95% CI 0.15 to 0.68); low disease activity status (LDAS) was associated with a lower risk of new damage (HR 0.66; 95% CI 0.48 to 0.93) compared with non-optimally controlled. No significant effect on mortality was observed.Conclusions: Remission was associated with a lower risk of new and severe new damage; LDAS with a lower risk of new damage after adjusting for other damage confounders. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
22. Early proteinuria response: a valid reallife situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis?
- Author
-
Ugolini-Lopes, Michelle R., Seguro, Luciana Parente C., Castro, Maitê Xavier F., Daffre, Danielle, Lopes, Alex C., Borba, Eduardo F., and Bonfá, Eloisa
- Published
- 2017
- Full Text
- View/download PDF
23. Macrophage activation syndrome: A severe and frequent manifestation of acute pancreatitis in 362 childhood-onset compared to 1830 adult-onset systemic lupus erythematosus patients.
- Author
-
Gormezano, Natali W.S., Otsuzi, Carini I., Barros, Diego L., da Silva, Mariana A., Pereira, Rosa M.R., Campos, Lucia M.A., Borba, Eduardo F., Bonfá, Eloisa, and Silva, Clovis A.
- Abstract
Objective We previously reported a case series of acute pancreatitis (AP) and macrophage activation syndrome (MAS) in childhood (cSLE) patients; however, there are no data regarding the comparison of AP and MAS in large populations of cSLE and adult SLE (aSLE). Methods A study included 362 cSLE and 1830 aSLE patients. MAS was diagnosed according to preliminary diagnostic guidelines and AP according to the presence of abdominal pain or vomiting associated to an increase of pancreatic enzymes and/or pancreatic radiological abnormalities. Demographic data, clinical features, SLEDAI-2K, SLICC/ACR-DI, and treatment were assessed. Results Age in MAS patients was significantly lower compared with those without this complication [15 (8.8–55) vs. 33.5 (10.2–45.7) years, p = 0.007]. The frequencies of fever (94% vs. 37%, p = 0.001), leucopenia (82% vs. 19%, p = 0.0001), thrombocytopenia (65% vs. 19%, p = 0.013), hypertriglyceridemia (87% vs. 42%, p = 0.037), and hyperferritinemia (93% vs. 37%, p = 0.011) were also more frequently observed in AP patients with MAS compared in AP patients without MAS. Fever and hyperferritinemia concomitantly were more frequent in the former group (86% vs. 12%, p = 0.0015). Higher and significant frequency of AP in cSLE compared to aSLE patients [12/362 (3.3%) vs. 20/1830 (1.1%), p = 0.003], with similar AP duration [22 (6–60) vs. 15 (4–90) days, p = 0.534]. MAS (85% vs. 30%, p = 0.003) and death by MAS complication (31% vs. 0%, p = 0.017) were significantly higher in children compared with aSLE. Conclusions This study provides novel data demonstrating that MAS occur in the majority of cSLE with AP with a higher mortality compared to aSLE. In addition, we identified in AP patients, a cluster of MAS clinical and laboratorial parameters more associated with this complication. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
24. Impact of Therapy on Metabolic Syndrome in Young Adult Premenopausal Female Lupus Patients: Beneficial Effect of Antimalarials.
- Author
-
Muniz, Luciana F., Pereira, Rosa M. R., Silva, Thiago F., Bonfá, Eloisa, Borba, Eduardo F., and Bonfá, Eloisa
- Subjects
CHLOROQUINE ,ANTIMALARIALS ,GLUCOCORTICOIDS ,PREDNISONE ,PROBABILITY theory ,SYSTEMIC lupus erythematosus ,PERIMENOPAUSE ,DISEASE prevalence ,METABOLIC syndrome ,CROSS-sectional method ,DISEASE complications ,PREVENTION ,THERAPEUTICS - Abstract
Objective: There are no data about the main factors associated with metabolic syndrome in young premenopausal systemic lupus erythematosus (SLE) patients. The aim of the study was to evaluate the frequency of metabolic syndrome and disease- or therapy-related factors in premenopausal young SLE patients.Methods: A total of 103 premenopausal SLE patients ages <40 years were selected and compared to 35 healthy premenopausal age-matched women. Metabolic syndrome was defined according to the 2009 Joint Interim Statement.Results: A higher frequency of metabolic syndrome (22.3% versus 5.7%; P = 0.03) was observed in the SLE group. Metabolic syndrome-SLE patients had higher SLE Disease Activity Index scores (mean ± SD 5.9 ± 7.6 versus 1.9 ± 2.7; P = 0.006), more frequently had previous renal disease (73.9% versus 51.2%; P = 0.05) and current renal disease (34.8% versus 10.0%; P = 0.008), and had higher current prednisone dose (median [range] 20 [0-60] versus 5 [0-60] mg/dl; P = 0.018) and cumulative prednisone dose (mean ± SD 41.48 ± 27.81 versus 24.7 ± 18.66 gm; P = 0.023) than those without metabolic syndrome. Chloroquine was less frequently used in metabolic syndrome-SLE patients (65.2% versus 90.0%; P = 0.008). In multivariate analysis, only current chloroquine use (prevalence ratio [PR] 0.29, 95% confidence interval [95% CI] 0.13-0.64) and cumulative prednisone were associated with metabolic syndrome (PR 1.02, 95% CI 1.01-1.04). Further estimated prevalence analysis identified the fact that antimalarial use promoted continuous decrease in the progressive metabolic syndrome prevalence associated with glucocorticoid cumulative dose.Conclusion: The prevalence of metabolic syndrome is high in premenopausal young adult SLE patients. Chloroquine has a protective effect on the prevalence of metabolic syndrome in these patients, and this benefit counteracts the deleterious effect of glucocorticoids in a dose-dependent manner. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.